MSI-H esophago-gastric cancer responds very well to checkpoint inhibitors
Keywords: Microsatellite instability, MSI, MMR, dMMR, mismatch repair, Lynch syndrome
Doi: (https://doi.org/10.1200/JCO.22.00686)
Landmark Phase 2 trial from France of 33 patients with advanced (T3N+M0) GEJ / Gastric cancer, with MSI-H, (22% of patients had Lynch syndrome) - achieved excellent clinical response with Ipilimumab / Nivolumab - with 60% patients achieving complete pathologic response found at planned surgery, 100% patients achieving R0 reponse!
Comments
Post a Comment